TACR1 and breast cancer: Furthermore, peptidergic system antagonists (e.g., neurokinin receptor 1 antagonist aprepitant, a morpholine derivative) in conjunction with chemotherapeutic drugs such as cisplatin or doxorubicin augmented the anticancer action against triple-negative BC cells and at the same time attenuated the harmful effects mediated by chemotherapy [13,14].